Doxorubicin is a highly effective chemotherapy drug the use of which is complicated by its well-established cardiotoxic side effect, with little potential for predicting which patients will be adversely affected. In this project, we are investigating the application of human induced pluripotent stem cell-derived cardiomyocytes to validate genetic markers of doxorubicin-induced cardiotoxicity and to establish the molecular mechanisms by which they alter the risk of this complication. This knowledge should be of value in prediction of doxorubicin-induced cardiotoxicity and this platform useful for studying means of prevention.
|Effective start/end date||9/1/15 → 8/31/18|
- National Heart, Lung, and Blood Institute (5R00HL121177-04)